A security alliance shaping the future of connected infrastructure

Tern plc

Device Authority’s KeyScaler platform has built its reputation on automating device identity at scale. Rather than relying on manual oversight, the system creates, rotates and retires digital identities across vast fleets of connected assets. For investors, the attraction is clear: this reduces exposure to breaches that often trace back to unmanaged or outdated credentials. But automation alone is only part of the equation. To be effective, these capabilities must be embedded into complex corporate ecosystems, which is where Optiv’s advisory strength comes into play.

The shift toward Zero Trust frameworks has sharpened the spotlight on machine identities. Unlike perimeter-based security, Zero Trust requires constant validation of every entity on the network. Device Authority’s identity-first approach fits directly into this narrative, while Optiv brings the experience needed to operationalise it for clients that span critical sectors such as energy, healthcare and manufacturing. The synergy points to a model where cyber defences are not bolted on as an afterthought but are woven into the operational fabric from the outset.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search